GSK Wins First Lung Cancer Approval With Jideytro, Days After Closing $10.6B Nuvalent Deal
The FDA's accelerated approval of zidesamtinib gives GSK its first lung cancer medicine and a foothold in a small but hard-to-treat group of ROS1-positive patients.
No articles yet.